{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:50:02Z","timestamp":1765486202598,"version":"3.40.5"},"reference-count":58,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["71704064"],"award-info":[{"award-number":["71704064"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Natural Science Foundation of Guangdong Province, China","award":["2017A030310174"],"award-info":[{"award-number":["2017A030310174"]}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"crossref","award":["21616324"],"award-info":[{"award-number":["21616324"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.clinthera.2018.05.012","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T02:55:56Z","timestamp":1531277756000},"page":"1122-1139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma"],"prefix":"10.1016","volume":"40","author":[{"given":"Tian-tian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zugui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7461-9509","authenticated-orcid":false,"given":"Jie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2018.05.012_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0002","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1182\/blood-2017-03-726703","article-title":"How I treat first relapse of myeloma","volume":"130","author":"Harousseau","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0003","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.critrevonc.2017.03.018","article-title":"Triplet versus doublet combination regimens for the treatment of relapsed or refractory multiple myeloma: a meta-analysis of phase III randomized controlled trials","volume":"113","author":"Sun","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0004","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2017.0023","article-title":"Multiple myeloma, version 3.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Kumar","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0005","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13045-016-0282-1","article-title":"Novel agents in the treatment of multiple myeloma: a review about the future","volume":"9","author":"Naymagon","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0006","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.2016.71.1663","article-title":"Systematic literature review and network meta-analysis of treatment outcomes in relapsed and\/or refractory multiple myeloma","volume":"35","author":"van Beurden-Tan","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0007","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/bloodadvances.2016003905","article-title":"Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed\/refractory patients","volume":"1","author":"Botta","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0008","doi-asserted-by":"crossref","first-page":"34001","DOI":"10.18632\/oncotarget.16987","article-title":"Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed\/refractory multiple myeloma","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0009","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.clinthera.2018.01.014","article-title":"Comparative efficacy of treatments for previously treated multiple myeloma: a systematic literature review and network meta-analysis","volume":"40","author":"Maiese","year":"2018","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0010","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0011","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2018.05.012_bib0012","first-page":"1852","article-title":"Chanan-Khan, Noemi Horvath. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone for relapsed\/refractory multiple myeloma (RRMM) patients: an update of overall survival in CASTOR","volume":"130","author":"Suzanne Lentzsch","year":"2017","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2018.05.012_bib0013","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood.V130.Suppl_1.739.739","article-title":"Daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): updated efficacy and safety analysis of Pollux","volume":"130","author":"Dimopoulos","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0014","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/j.clinthera.2017.08.010","article-title":"Cost-effectiveness of pomalidomide, carfilzomib, and daratumumab for the treatment of patients with heavily pretreated relapsed-refractory multiple myeloma in the United States","volume":"39","author":"Pelligra","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0015","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1200\/JCO.2016.69.6336","article-title":"Cost-effectiveness of immune checkpoint inhibition in BRAF wild-type advanced melanoma","volume":"35","author":"Kohn","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0016","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-11-139","article-title":"Improved curve fits to summary survival data: application to economic evaluation of health technologies","volume":"11","author":"Hoyle","year":"2011","journal-title":"Bmc Medical Research Methodology"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0017","unstructured":"SEER. Surveillance, epidemiology, and end results program. Stat fact sheets: Myeloma. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed September 2017."},{"key":"10.1016\/j.clinthera.2018.05.012_bib0018","first-page":"1","article-title":"United States Life Tables, 2011","volume":"64","author":"Arias","year":"2015","journal-title":"Natl Vital Stat Rep"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0019","unstructured":"Centers for Medicare & Medicaid Services: 2017 ASP drug pricing files. https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Part-B-Drugs\/McrPartBDrugAvgSalesPrice\/2017ASPFiles.html. Accessed July 2017."},{"key":"10.1016\/j.clinthera.2018.05.012_bib0020","unstructured":"Truven Health Analytics MicroMedex Solutions, 2017."},{"key":"10.1016\/j.clinthera.2018.05.012_bib0021","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","article-title":"Simplified calculation of body-surface area","volume":"317","author":"Mosteller","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0022","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1080\/17474086.2017.1391088","article-title":"Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States","volume":"10","author":"Jakubowiak","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0023","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/13696998.2016.1194278","article-title":"Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective","volume":"19","author":"Jakubowiak","year":"2016","journal-title":"J Med Economics"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0024","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1634\/theoncologist.2011-0380","volume":"18","author":"Garrison","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0025","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3111\/13696998.2012.760159","article-title":"Total cost comparison in relapsed\/refractory multiple myeloma","volume":"16","author":"Durie","year":"2013","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0026","unstructured":"Janssen Biotech I, Horsham, PA 19044 U.S. License Number 1864. DARZALEX (daratumumab) injection, for intravenous use [prescribing information], Revision June 2017."},{"key":"10.1016\/j.clinthera.2018.05.012_bib0027","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3111\/13696998.2015.1115407","article-title":"Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma","volume":"19","author":"Usmani","year":"2016","journal-title":"J Med Econ"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2018.05.012_bib0028","first-page":"3145","article-title":"Daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): updated efficacy and safety analysis of Castor","volume":"130","author":"Andrew Spencer","year":"2017","journal-title":"Blood"},{"year":"2015","series-title":"Restrospective study of healthcare utilization and costs in patients with multiple myeloma using Truven MarketScan Data Through December 2014","key":"10.1016\/j.clinthera.2018.05.012_bib0029"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0030","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/archinternmed.2009.509","article-title":"Clinical and Economic Outcomes Attributable to Health Care-Associated Sepsis and Pneumonia","volume":"170","author":"Eber","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0031","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10198-012-0395-6","article-title":"Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales","volume":"14","author":"Brown","year":"2013","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0032","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3111\/13696998.2011.611841","article-title":"Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib","volume":"14","author":"Moller","year":"2011","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0033","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.ejca.2004.01.019","volume":"40","author":"van Agthoven","year":"2004","journal-title":"Eur J Cancer"},{"year":"2017","series-title":"Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib","key":"10.1016\/j.clinthera.2018.05.012_bib0034"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0035","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/CMAR.S43373","article-title":"Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece","volume":"5","author":"Fragoulakis","year":"2013","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0036","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3111\/13696998.2015.1115407","article-title":"Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma","volume":"19","author":"Usmani","year":"2016","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0037","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating Cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"year":"2007","series-title":"Bortezomib monotherapy for relapsed multiple myeloma","key":"10.1016\/j.clinthera.2018.05.012_bib0038"},{"year":"2017","series-title":"Carfilzomib for previously treated multiple myeloma","key":"10.1016\/j.clinthera.2018.05.012_bib0039"},{"year":"2016","series-title":"Panobinostat for treating multiple myeloma after at least 2 previous treatments","key":"10.1016\/j.clinthera.2018.05.012_bib0040"},{"year":"2017","series-title":"Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy","key":"10.1016\/j.clinthera.2018.05.012_bib0041"},{"year":"2017","series-title":"Daratumumab for treating relapsed or refractory multiple myeloma","key":"10.1016\/j.clinthera.2018.05.012_bib0042"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0043","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","article-title":"American Society of Clinical Oncology Statement: a conceptual framework to assess the value of cancer treatment options","volume":"33","author":"Schnipper","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0044","unstructured":"Congressional Budget Office. Increasing the value of federal spending on health care. http:\/\/www.cbo.gov\/ftpdocs\/95xx\/doc9563\/07-16-HealthReform.1.2.shtml."},{"key":"10.1016\/j.clinthera.2018.05.012_bib0045","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0140-6736(16)30954-0","article-title":"Multiple myeloma\u2014translation of trial results into reality","volume":"388","author":"Moreau","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0046","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1182\/blood-2016-09-692947","article-title":"Next-generation multiple myeloma treatment: a pharmacoeconomic perspective","volume":"128","author":"Rajkumar","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0048","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1002\/cncr.30818","article-title":"Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation","volume":"123","author":"Hui","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0049","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1002\/cncr.28330","article-title":"Cancer drug prices and the free-market forces","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0050","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1002\/cncr.30666","article-title":"Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives","volume":"123","author":"Wan","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0051","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0052","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0053","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0054","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0055","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0056","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0057","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","article-title":"Health state utilities for metastatic breast cancer","volume":"95","author":"Lloyd","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0058","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00019053-200725030-00005","article-title":"Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods","volume":"25","author":"Ossa","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2018.05.012_bib0059","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1525-1497.1999.00320.x","article-title":"Racial differences in patients' perceptions of debilitated health states","volume":"14","author":"Cykert","year":"1999","journal-title":"J Gen Intern Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181830239X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181830239X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T05:39:50Z","timestamp":1661578790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929181830239X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S014929181830239X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.05.012","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}